Tesamorelin Dosage Chart: The Label Exists, and Says Something Narrow

Summary: Unusually for a peptide sold this way, there is an approved label to point at. What it authorises is much narrower than what the compound is marketed for.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Most compounds covered on this site have no approved label anywhere, which is why dosing pages about them can only report what animal studies used. Tesamorelin is the exception, and the exception is worth understanding before reading any chart about it.

There is an approved product

Tesamorelin is approved by the FDA and marketed as EGRIFTA, latterly EGRIFTA SV, under biologics licence application BLA 022505, held by Theratechnologies. It is a prescription powder for reconstitution, not a research chemical in its approved form.

That means a dosage chart for tesamorelin is doing something a chart for BPC-157 or MOTS-c cannot: restating quantities that a regulator reviewed and authorised.

What the label actually authorises

Here is the part most pages skip. The approved indication is narrow and specific:

EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

The same section carries a limitation of use stating that long-term cardiovascular safety has not been established, and directing prescribers to weigh risk and benefit in patients who have not seen a reduction in visceral adipose tissue.

So the label covers one population, HIV-infected adults with lipodystrophy, and one outcome, reduction of excess abdominal fat. It does not authorise the compound for general body composition, for athletic recovery, or for anti-ageing, which is what most of the marketing around it concerns.

Why that distinction decides how to read a chart

An approved indication is not a suggestion about who might benefit. It is the boundary of what the evidence supported and what the regulator was willing to license, and everything outside it is unstudied in the regulatory sense even when the compound itself is well characterised.

A tesamorelin dosage chart that restates the approved quantities is reporting something real. A chart that presents those same quantities for a purpose the label does not cover has quietly moved from reporting to extrapolating, and the numbers look identical either way.

Twenty-four studies are registered on ClinicalTrials.gov under the name, which is a real research base by the standards of this category.

The practical read

If you are looking at a chart for this compound, two questions settle most of it. Does it name the approved indication, or does it present quantities with no population attached? And does it distinguish the approved product from material sold as a research chemical, which carries no labelled mass anyone verified?

A compound having an approved label is genuinely good news for anyone trying to check a number. It only helps if the chart tells you what the label was for.